Top rated colorectal cancer clinical trials in New York, New York
Here are the top 10 medical studies for colorectal cancer in New York, New York
Popular filter options for colorectal-cancer new-york trials
Phase 3 Clinical Trials
View 97 phase 3 medical studies.
Chemotherapy
Chemotherapy + Atezolizumab for Colon Cancer
Recruiting2 awardsPhase 3
Fairfield, Connecticut
This trial is testing a combination of chemotherapy drugs with atezolizumab to see if it is more effective than chemotherapy alone in treating patients with stage III colon cancer. Atezolizumab is an immunotherapy drug that may help the body's immune system attack the cancer.
Checkpoint Inhibitor
Nivolumab + Ipilimumab for Colorectal Cancer
Recruiting2 awardsPhase 3
New York, New York
This trial is testing nivolumab with or without ipilimumab as a treatment for metastatic colorectal cancer in patients with microsatellite instability high or mismatch repair deficiency. The goal is to see if the combination therapy is more effective than nivolumab alone and if either treatment is more effective than chemotherapy.
Clinical Trials With No Placebo
View 97 medical studies that do not have a placebo group.
XPO1 inhibitor
KPT-8602 for Multiple Myeloma
Recruiting1 awardPhase 1 & 2
New York, New York
This trial will assess the safety, tolerability, and preliminary efficacy of KPT-8602, an oral XPO1 inhibitor, in patients with relapsed/refractory multiple myeloma, metastatic colorectal cancer, metastatic castration resistant prostate cancer, higher risk myelodysplastic syndrome, acute myeloid leukemia, and newly diagnosed intermediate/high-risk MDS.
PARP Inhibitor
M6620 + Irinotecan for Cancer
Recruiting1 awardPhase 1
New Haven, Connecticut
This trial is studying the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with metastatic solid tumors. M6620 and irinotecan hydrochloride may stop the growth of tumor cells.
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
Recruiting1 awardPhase 2
New York, New York
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
View More Colorectal-cancer New-york Trials
See another 79 medical studies focused on colorectal-cancer new-york.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.